Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heidi Mocikova

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
European Journal of Haematology|September 3, 2011
Reply to the letter to the editor by Guinn et alJosef Karban, Heidi Mocikova, Robert Pytlik, et al.
Leukemia & Lymphoma|April 7, 2012
Rituximab-induced coagulopathyJan Novak, Heidi Mocikova, Petr Pavlicek, et al.
Leukemia & Lymphoma|January 15, 2013
BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphomaMonika Palickova, Heidi Mocikova, Zdenka Vernerova, et al.
Annals of Hematology|September 8, 2022
Circulating tumor DNA in Hodgkin lymphomaMaria Maco, Kristyna Kupcova, Vaclav Herman, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 29, 2008
Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: results from the prospective randomized trial PRAGUE 11-Coronary Artery Bypass and REactivity of Thrombocytes (CABARET)Frantisek Bednar, Pavel Osmancik, Tomas Vanek, et al.
Expert Review of Molecular Diagnostics|May 6, 2025
Circulating tumor DNA as a powerful tool in diagnostics and treatment outcome prediction - focus on large B-cell lymphomas and follicular lymphomasIva Hamova, Maria Maco, Anton Tkachenko, et al.
Leukemia Research|May 7, 2011
No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphomaOndrej Havranek, Martin Spacek, Petr Hubacek, et al.
Acta Haematologica|May 30, 2015
Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?Heidi Mocikova, Robert Pytlik, Pavla Stepankova, et al.
Leukemia & Lymphoma|April 19, 2016
Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registryHeidi Mocikova, Robert Pytlik, Alice Sykorova, et al.
Leukemia & Lymphoma|August 4, 2017
Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphomaWojciech Jurczak, Sundra Ramanathan, Pratyush Giri, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
European Journal of Haematology|September 3, 2011
Reply to the letter to the editor by Guinn et alJosef Karban, Heidi Mocikova, Robert Pytlik, et al.
Leukemia & Lymphoma|April 7, 2012
Rituximab-induced coagulopathyJan Novak, Heidi Mocikova, Petr Pavlicek, et al.
Leukemia & Lymphoma|January 15, 2013
BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphomaMonika Palickova, Heidi Mocikova, Zdenka Vernerova, et al.
Annals of Hematology|September 8, 2022
Circulating tumor DNA in Hodgkin lymphomaMaria Maco, Kristyna Kupcova, Vaclav Herman, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 29, 2008
Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: results from the prospective randomized trial PRAGUE 11-Coronary Artery Bypass and REactivity of Thrombocytes (CABARET)Frantisek Bednar, Pavel Osmancik, Tomas Vanek, et al.
Expert Review of Molecular Diagnostics|May 6, 2025
Circulating tumor DNA as a powerful tool in diagnostics and treatment outcome prediction - focus on large B-cell lymphomas and follicular lymphomasIva Hamova, Maria Maco, Anton Tkachenko, et al.
Leukemia Research|May 7, 2011
No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphomaOndrej Havranek, Martin Spacek, Petr Hubacek, et al.
Acta Haematologica|May 30, 2015
Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?Heidi Mocikova, Robert Pytlik, Pavla Stepankova, et al.
Leukemia & Lymphoma|April 19, 2016
Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registryHeidi Mocikova, Robert Pytlik, Alice Sykorova, et al.
Leukemia & Lymphoma|August 4, 2017
Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphomaWojciech Jurczak, Sundra Ramanathan, Pratyush Giri, et al.
Pageof 4